期刊文献+

一氧化氮供体型双水杨酸酯衍生物的合成及降血糖活性

Synthesis and hypoglycemic activities of nitric oxide-donating salsalate derivatives
下载PDF
导出
摘要 目的:研究一氧化氮(NO)供体型双水杨酸酯衍生物的合成和降血糖活性,寻找治疗糖尿病的有效药物。方法:以双水杨酸酯为先导化合物,通过各种连接基团,将硝酸酯类NO供体与双水杨酸酯的2′位羧基连接,分别制得目标物2a-2e、4a、4b、6a、6b。应用GOD-POD法测定目标物增加HepG2细胞耗糖量的作用,应用Griess法测定目标物体外NO释放量。结果:合成了9个目标物,其结构经IR、1HNMR、MS等确证;所有目标物均有不同程度的降血糖活性,其中化合物2a、2b、4b的活性优于双水杨酸酯。结论:NO供体型双水杨酸酯衍生物可能通过释放NO,增强了双水杨酸酯的降血糖活性。其中,化合物2a的活性较强,值得进一步研究。 Aim: To study the synthesis and hypoglycemic activities of nitric oxide-donating salsalate derivatives and search for novel anti-diabetic agents. Methods: Using salsalate as a lead compound, nitrates were incorporated to 2'-carboxyphenyl of salsalate via a variety of linkers, giving target compounds 2a-2e, 4a, 4b, 6a and 6b. And the compounds' activities of increasing the glucose consumption in liver tumor cells were evaluated by GOD-POD assay. In addition, NO-release of the compounds was determined by Griess assay. Results: The structures of all the target compounds were confirmed by IR, MS and ^1H NMR. The screening results demonstrated that all tested compounds exhibited hypoglycemic activities to various extents, especially compound 2a, 2b, 4b showing more potent activity than salsalate did. Conclusion: The hypoglycemic activities of NO-donating salsalate derivatives are probably by NO-release mechanism. Compound 2a is promising for further investigation.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2008年第4期301-305,共5页 Journal of China Pharmaceutical University
关键词 双水杨酸酯 硝酸酯 一氧化氮供体 合成 降血糖活性 salsalate nitrates nitric oxide donor synthesis hypoglycemic activity
  • 相关文献

参考文献12

  • 1洪岭,张胜兰.抗炎与2型糖尿病[J].国际内分泌代谢杂志,2007,27(2):118-120. 被引量:10
  • 2Fleisehman A, Shoelson SE, Bernier R, et al. Salsalate improves glyeemia and inflammatory parameters in obese young adults[ J ]. Diabetes Care,2008,31 (2) :289 -294.
  • 3Hays NP, Galassetti PR, Coker RH. Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions [ J ] . Pharmacol Ther, 2008,118 (2) :181 -191.
  • 4Sandrim VC, de Syllos RW, Lisboa HR. Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients [ J ]. Nitric Oxide, 2007,16(3 ) :348 - 355.
  • 5Gokcea G, Haznedaroglu MZ. Evaluation of antidiabetic, antioxidant and vasoprotective effects of Posidonia oceanica extract [ J]. J Ethnopharmacol,2008,115 ( 1 ) : 122 - 130.
  • 6Mohan IK, Das UN. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus [ J ] . Free Radic Biol Med, 1998,25(7) :757 -765.
  • 7刘志军,仲伯华.一氧化氮供体修饰非甾体类抗炎药研究进展[J].国际药学研究杂志,2007,34(6):414-418. 被引量:1
  • 8Ambrosini MV, Mariucci G, Rambotti MG, et al. Ultrastructural investigations on protective effects of NCX-4016 (nitroaspirin) on macrovascular endothelium in diabetic Wistar rats [ J ]. J Submicrosc Cytol Pathol,2005,37 ( 2 ) :205 - 213.
  • 9Burke SG, Wainwright CL, Vojnovic I, et al. The effect of NCXd016 [ 2-acetoxy-benzoate 2-( 2-nitroxymethyl )-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat[ J]. J Pharmacol Exp Ther,2006,316 (3) :1 107-1114.
  • 10Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX4016 ,a nitric oxide-releasing aspirin,for cardiovascular disorders [ J ]. Cardiovasc Drug Rev, 2006,24 ( 2 ) : 148 - 168.

二级参考文献20

  • 1刘颖,刘志民,赵瑛,何金,刘会敏,董艳.罗格列酮对胰岛素抵抗大鼠肾皮质内皮素1及内皮型一氧化氮合酶表达的影响[J].中华肾脏病杂志,2005,21(3):157-160. 被引量:3
  • 2Guang-Dong Pan,Hong Wu,Jiang-Wen Liu,Nan-Sheng Cheng,Xian-Ze Xiong,Sheng-Fu Li,Suo-Fu Zhang,Lu-Nan Yan.Effect of peroxisome proliferator-activated receptor-gamma ligand on inflammation of human gallbladder epithelial cells[J].World Journal of Gastroenterology,2005,11(38):6061-6065. 被引量:3
  • 3[1]Tuteja N,Chandra M,Tuteja R,et al.Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology[J].J Biomed Biotechnol,2004,2004(4):227-237.
  • 4[2]Ongini E,Bolla M.Nitric-oxide based nonsteroidal anti-inflammatory agents[J].Drug Discov Today Therapeutic Strategies,2006,3(3):395-400.
  • 5[3]Hawkey CJ,Jones JI,Atherton CT,et al.Gastrointestinal safety of AZD3582,a cyclooxygenase inhibiting nitric oxide donator:proof of concept study in humans[J].Gut,2003,52(11):1537-1542.
  • 6[4]Schnitzer TJ,Kivitz AJ,Lipetz RS,et al.Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee[J].Arthritis Rheum,2005,53(6):827-837.
  • 7[5]Young DV,Cochran ED,Dhawan V,et al.A comparison of the cyclooxygenase inhibitor-NO donors (CINOD),NMI-1182 and AZD3582,using in vitro biochemical and pharmacological methods[J].Biochem Pharmacol,2005,70(9):1343-1351.
  • 8[6]Yeh RK,Chen J,Willams JL,et al.NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs:a general pharmacological property?[J].Biochem Pharmacol,2004,67(12):2197-2205.
  • 9[7]Kashfi K,Rayyan Y,Qiao LL,et al.Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells:evidence of a tissue type-independent effect[J].J Pharmacol Exp Ther,2002,303(3):1273-1282.
  • 10[8]Huguenin S,Vacherot F,Fleury-Feith J,et al.Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines[J].Cancer lett,2005,218(2):163-170.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部